Breakthrough by Israeli Scientists Enhances Immune System to Target Cancer

A groundbreaking study led by Professor Mira Barda-Saad and her research team at Bar-Ilan University has unveiled an innovative technique to rejuvenate natural killer (NK) cells, a key component of the immune system, in the fight against cancer. Published on the cover of The EMBO Journal, this research addresses a significant challenge in cancer immunotherapy: NK cell exhaustion.

Natural killer cells play a crucial role in identifying and destroying cancerous and viral cells. However, these vital cells can become "exhausted" after prolonged exposure to tumors, losing their effectiveness in combating cancer. This discovery has posed a considerable obstacle for immunotherapeutic strategies, which have been transformative in cancer treatment over recent years.

One such strategy, the Chimeric Antigen Receptor (CAR) approach, involves genetically modifying a patient’s cells to enhance their cancer-fighting capabilities before reintroducing them into the body. While effective, this method is complex and requires the extraction and genetic manipulation of cells.

To overcome the limitations of NK cell exhaustion, Prof. Barda-Saad’s team identified the underlying causes of NK cell dysfunction and developed a novel solution using nanoparticles. These nanoparticles target and silence specific negative regulators within the NK cells, restoring their activity directly within the patient’s body and eliminating the need for cell extraction and genetic modification.

NK cell dysfunction can arise from two primary sources: disruptions during their development process, known as “anergy,” and prolonged, excessive stimulation in the tumor microenvironment, leading to “exhaustion.” Both conditions result in NK cells losing their ability to effectively combat cancer. Prof. Barda-Saad’s research is the first to thoroughly characterize these dysfunctional processes and offer a potential solution.

The research team identified two key contributors to NK cell dysfunction: the enzyme DGK alpha and the transcription factor Egr2. By introducing nanoparticles designed to silence these negative regulators, the team successfully reprogrammed the dysfunctional NK cells, restoring their normal function and enabling them to efficiently kill cancer cells.

Experiments conducted in three-dimensional tissue cultures and in vivo mice models demonstrated the effectiveness of this approach. The restored NK cells showed significant improvements in their ability to target and destroy cancer cells, particularly in models of aggressive pancreatic cancer.

These promising findings could pave the way for the development of highly effective treatments against solid tumors using this immunotherapeutic strategy. As Prof. Barda-Saad’s research progresses, it offers renewed hope to cancer patients and professionals in the field, potentially revolutionizing the way cancer is treated by harnessing the body’s immune system.

Stay informed on the latest advancements in medical research by subscribing to our newsletter.